News | Pharmaceuticals | May 13, 2022

Bristol Myers Squibb’s Mavacamten Poised to Stand unchallenged

Mavacamten estimated sales just shy of $1 billion if approved for common cardiomyopathy subtype, says GlobalData

Mavacamten estimated sales just shy of $1 billion if approved for common cardiomyopathy subtype, says GlobalData

Getty Images


May 13, 2022 — Bristol Myers Squibb’s mavacamten will stand rather unchallenged in the hypertrophic cardiomyopathy (HCM) market, achieving around $958 million in sales by 2025, according to GlobalData, a leading data and analytics company.

Sarah Bundra, Pharmaceutical Analyst at GlobalData, commented: “Mavacamten will be the first drug to specifically target obstructive HCM, which is a common form of cardiomyopathy. It has a unique mechanism of action (MoA)—being a myosin inhibitor—that more closely targets the pathophysiology of the disease.”

Existing cardiomyopathy therapies are generic and used for a wide range of cardiovascular diseases. Mavacamten can be used in conjunction with marketed therapies, such as beta blockers. As such, the drug will not displace any current therapy options, but will address a key cardiomyopathy demographic that has not previously been the target of clinical trial development.

Mavacamten’s performance in the VALOR-HCM study—whereby only 18% of participants still needed surgical intervention after 16 weeks—highlight its strength and potential in this market. This is even more impressive compared to placebo, of which 77% still needed surgery after the same time frame. Mavacamten has proved it can offer patients a chance to avoid invasive and costly procedures. Other reports from the VALOR-HCM study show that the majority of patients requested to continue the drug after the 16-week study period, suggesting a favorable safety profile.

Bundra adds: “Dr. Desai’s VALOR-HCM study results give obstructive HCM patients reasons to be excited.”

For more information: https://www.globaldata.com/

More ACC22 coverage can be found here

Related content:

Mavacamten Dramatically Cuts Need for Surgical Intervention for People with Obstructive Hypertrophic Cardiomyopathy

Cardiogenic Shock Market Outlook

ACC22: Transforming Cardiovascular Care

FDA Approves Bristol Myers' Camzyos (mavacamten) Oral Heart Disease Drug

Related Content

News | ACC

July 15, 2022 — The ACC has named Melvin R. Echols, MD, FACC, as its new Chief Diversity, Equity and Inclusion Officer ...

Home July 15, 2022
Home
Feature | ACC | By Melinda Taschetta-Millane

In April, the cardiology community converged face-to-face in Orlando for The American College of Cardiology’s (ACC22) ...

Home May 11, 2022
Home
News | ACC

April 12, 2022 – The American College of Cardiology (ACC) is establishing a new award in honor of Valentin Fuster, MD ...

Home April 12, 2022
Home
News | ACC
April 4, 2022 – Esperion presented two new analyses from its clinical development program of bempedoic acid (NEXLETOL) ...
Home April 04, 2022
Home
News | ACC

April 3, 2022 — egnite, Inc., an advanced technology digital health company focused on providing artificial intelligence ...

Home April 03, 2022
Home
News | ACC

April 3, 2022 — A new drug shows promise in providing relief to cardiomyopathy patients experiencing shortness of breath ...

Home April 03, 2022
Home
News | ACC

April 1, 2022 — Royal Philips, a global leader in health technology, announced new additions to its innovative ...

Home April 01, 2022
Home
News | ACC
March 31, 2022 – Healthcare AI solutions provider Aidoc will be delivering a live demonstration of its comprehensive AI ...
Home March 31, 2022
Home
News | ACC
March 31, 2022 – Experts from the Smidt Heart Institute at Cedars-Sinai, home to California’s top-ranked cardiology and ...
Home March 31, 2022
Home
News | ACC
March 31, 2022 – CathWorks has announced that the results of its most recent outcomes study on the CathWorks FFRangio ...
Home March 31, 2022
Home
Subscribe Now